INTERCEPT-AMD
Research type
Research Study
Full title
A collaborative resource of Heidelberg multimodal imaging of Intermediate AMD with and without early atrophy to study prediction of disease progression
IRAS ID
326750
Contact name
Sobha Sivaprasad
Contact email
Sponsor organisation
AIBILI – Association for Innovation and Biomedical Research on Light and Image
Clinicaltrials.gov Identifier
NCT05698316, ClinicalTrials.gov Identifier
Duration of Study in the UK
1 years, 9 months, 2 days
Research summary
Age-related macular degeneration (AMD) is the commonest cause of visual impairment in older people in Europe. It is a slowly progressing complex disorder. The clinical progression is best described as early, intermediate, and advanced based on the latest classification system on colour fundus photographs. However, multimodal imaging has enabled visualisation of further changes in the retina on optical coherence tomography (OCT), infrared imaging, and autofluorescence. So, a large database of imaging data of intermediate AMD will facilitate researchers to study the disease progression in detail. This study is a collaborative effort by investigators across many Member Sites in Europe that are members of EVICR.net to pool datasets for secondary analysis.
EVICR.net is a network of Ophthalmological Clinical Research Sites, dedicated to performing multinational clinical research in ophthalmology with the highest standards of quality, following the European and International Directives for Clinical Research in order to strengthen the capacity of the European Union to study the determinants of ophthalmic diseases and to develop and optimise the use of diagnostic, prevention and treatment strategies in ophthalmology.
EVICR.net Eye Platform is a long-term initiative to establish a platform to gather high quality ophthalmology data generated in Europe and allow the secondary use of data in performing large data analysis and foster clinical research.
With this Eye Platform EVICR.net aims to provide technological solutions that allow overcoming privacy and regulation issues associated with the sharing of data from different institutions/countries, in a secure, easy to use manner.
With EVICR.net Eye Platform, the Members Sites will have the opportunity to participate in clinical research with secondary use data analysis; Authorship of publications and presentations of Results; the opportunity to propose new analysis to answer key research questions; and increase overall visibility and stature as researchersREC name
South Central - Oxford B Research Ethics Committee
REC reference
23/SC/0216
Date of REC Opinion
19 Jun 2023
REC opinion
Favourable Opinion